The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Retrospective Analysis of Therapeutic Drug Monitoring Data for Treatment of Bipolar Disorder with Lamotrigine
Open accessAbstract
INTRODUCTION: Lamotrigine is licensed for treatment of epilepsy and prevention or at least delay of depressive episodes in bipolar disorder. The accepted therapeutic reference range (TRR) of lamotrigine for anticonvulsant treatment is 3 000-14 000 ng/ml. This TRR is often used for the therapy of bipolar disorders as well. This work presents serious doubts about this approach. METHODS: KONBEST, a large TDM database containing patients' characteristics including diagnoses, doses, comedication and serum concentrations, was analyzed. Out of a total of 3 459 lamotrigine samples, 360 patients suffered from bipolar disorder. 82 of them benefitted from therapy with lamotrigine as judged by the clinical global impression of improvement (CGI-I) scale. Patients with a score of minimally (3), much (2) or very much improved (1) were considered as responders. RESULTS: The recommended lamotrigine maintenance dose for bipolar disorder is 200 mg/day; the doses prescribed in our samples ranged from 25 to 450 mg/day. Only 32 concentrations (39.0%) fitted into the TRR recommended for therapy of epilepsy; 50 (61.0%) did not reach it, none exceeded it. The lowest concentration was 177 ng/ml, the highest 11 871 ng/ml. A mean lamotrigine serum concentration of 3 341±2 563 ng/ml (̅x±SD) was detected in the patients who benefitted. DISCUSSION: The authors conclude that in bipolar disorder lower lamotrigine serum concentrations lead to therapeutic benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Across several different medications for bipolar depression, early improvement (after 2 weeks) has been found to be a reasonable predictor of overall response, whereas lack of early improvement is a more robust predictor of non‐response.255”
From Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder (2018) · cites this paper as [255]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K. M., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 874
Self-citationGoa, K. L., Ross, S. R., & Chrisp, P. (1993) · Drugs · doi:10.2165/00003495-199346010-00009 · Cited by 308
Calabrese, J. R., Huffman, R., White, R. L., Edwards, S., Thompson, T. R., Ascher, J. A., Monaghan, E., & Leadbetter, R. A. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00500.x · Cited by 247
Hussein, Z., & Posner, J. (1997) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1997.00594.x · Cited by 140
Therapeutic Drug Monitoring in Pharmacovigilance and Pharmacotherapy Safety
Haen, E. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286285 · Cited by 44
Self-citationWalden, J., Schaerer, L., Schlösser, S., & Grunze, H. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.020408.x · Cited by 40
Kagawa, S., Mihara, K., Nakamura, A. M., Nemoto, K., Suzuki, T., Nagai, G., & Kondo, T. (2014) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000088 · Cited by 32
Greiner, C., & Haen, E. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.04.006 · Cited by 31
Self-citationTherapeutic Window of Lamotrigine for Mood Disorders: A Naturalistic Retrospective Study
Katayama, Y., Terao, T., Kamei, K., Hatano, K., Kohno, K., Makino, M., Mizokami, Y., Kodama, K., & Itoh, H. (2014) · Pharmacopsychiatry · doi:10.1055/s-0034-1375618 · Cited by 19
Konbest – A Web-Based Laboratory Information Management System (LIMS) for TDM-Laboratories
Koestlbacher, A., & Haen, E. (2008) · Pharmacopsychiatry · doi:10.1055/s-0028-1088261 · Cited by 12
Self-citationGreiner, C., Wittmann, M., & Haen, E. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-985886 · Cited by 3
Self-citation
Research works printed but not linked: 5
- Guy W, edited by Rush AJ. Clinical Global Impressions Scale (CGI). Handbook of Psychiatric Measures. Washington, DC: American Psy- chiatric Association; 2000: 100-102
- World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guide- lines. World Health Organization; 1992: 50-51
- Haen E, Greiner C, Bader W et al. Wirkstoffkonzentrationsbestimmun- gen zur Therapieleitung -Ergänzung therapeutischer Referenzbere- iche durch dosisbezogene Referenzbereiche (Engl. abstract: Expanding therapeutic reference ranges using dose-related reference ranges). Der Nervenarzt 2008; 79: 558-566
- Haen E. Der TDM-Befund (Engl. abstract: The TDM Report). Psychop- harmakotherapie 2012; 19: 129-134
- Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H. ‐., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K. M., Gerlach, M., Greiner, C., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,535
Self-citationManagement of bipolar depression with lamotrigine: an antiepileptic mood stabilizer
Prabhavalkar, K. S., Poovanpallil, N. B., & Bhatt, L. K. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00242 · Cited by 76
Eap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 51
Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes
Biso, L., Aringhieri, S., Carli, M., Scarselli, M., & Longoni, B. (2024) · Pharmaceuticals · doi:10.3390/ph17050642 · Cited by 49
Metadata
- Authors
- Unholzer, S., & Haen, E.
- Affiliations
- University of Regensburg (DE)
- Corresponding author
- Unholzer, S.
- ORCID
- Haen, E.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-08-07
- Volume
- 48
- Issue
- 06
- Pages
- 211-214
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2259338861
- Cited by
- 22
- References
- 11
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 1
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- lamotrigine, bipolar disorder, therapeutic drug monitoring, serum drug concentration, therapeutic window, anticonvulsant dosing, treatment response, dose-concentration relationship
- MeSH terms
- Lamotrigine, Adult, Aged, Aged, 80 and over, Anticonvulsants, Bipolar Disorder, Dose-Response Relationship, Drug, Female, Humans, Male, Retrospective Studies, Triazines, Drug Monitoring, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
